These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
335 related articles for article (PubMed ID: 30927016)
1. PD-L1 Ameliorates Murine Acute Graft-Versus-Host Disease by Suppressing Effector But Not Regulatory T Cells Function. Tang L; Ma S; Gong H; Wang J; Xu Y; Wu D; Sun A Arch Immunol Ther Exp (Warsz); 2019 Jun; 67(3):179-187. PubMed ID: 30927016 [TBL] [Abstract][Full Text] [Related]
3. Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway. Chen D; Tang P; Liu L; Wang F; Xing H; Sun L; Jiang Z Cell Cycle; 2018; 17(7):858-867. PubMed ID: 29493401 [TBL] [Abstract][Full Text] [Related]
4. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. Saha A; O'Connor RS; Thangavelu G; Lovitch SB; Dandamudi DB; Wilson CB; Vincent BG; Tkachev V; Pawlicki JM; Furlan SN; Kean LS; Aoyama K; Taylor PA; Panoskaltsis-Mortari A; Foncea R; Ranganathan P; Devine SM; Burrill JS; Guo L; Sacristan C; Snyder NW; Blair IA; Milone MC; Dustin ML; Riley JL; Bernlohr DA; Murphy WJ; Fife BT; Munn DH; Miller JS; Serody JS; Freeman GJ; Sharpe AH; Turka LA; Blazar BR J Clin Invest; 2016 Jul; 126(7):2642-60. PubMed ID: 27294527 [TBL] [Abstract][Full Text] [Related]
5. Reactive glia promote development of CD103 Prasad S; Hu S; Sheng WS; Chauhan P; Lokensgard JR Immun Inflamm Dis; 2018 Jun; 6(2):332-344. PubMed ID: 29602245 [TBL] [Abstract][Full Text] [Related]
6. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Saha A; Aoyama K; Taylor PA; Koehn BH; Veenstra RG; Panoskaltsis-Mortari A; Munn DH; Murphy WJ; Azuma M; Yagita H; Fife BT; Sayegh MH; Najafian N; Socie G; Ahmed R; Freeman GJ; Sharpe AH; Blazar BR Blood; 2013 Oct; 122(17):3062-73. PubMed ID: 24030385 [TBL] [Abstract][Full Text] [Related]
7. HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Yao Y; Wang L; Zhou J; Zhang X J Transl Med; 2017 Feb; 15(1):28. PubMed ID: 28183349 [TBL] [Abstract][Full Text] [Related]
8. Anti-IL-22 Antibody Attenuates Acute Graft-versus-Host Disease via Increasing Foxp3 Wu J; Gu J; Zhou S; Lu H; Lu Y; Lu L; Wang X J Immunol Res; 2018; 2018():1605341. PubMed ID: 30159338 [TBL] [Abstract][Full Text] [Related]
9. High expression of heme oxygenase-1 in target organs may attenuate acute graft-versus-host disease through regulation of immune balance of TH17/Treg. Yu M; Wang J; Fang Q; Liu P; Chen S; Zhe N; Lin X; Zhang Y; Zhao J; Zhou Z Transpl Immunol; 2016 Jul; 37():10-17. PubMed ID: 27168057 [TBL] [Abstract][Full Text] [Related]
10. Blocking activator protein 1 activity in donor cells reduces severity of acute graft-versus-host disease through reciprocal regulation of IL-17-producing T cells/regulatory T cells. Park MJ; Moon SJ; Lee SH; Kim EK; Yang EJ; Min JK; Park SH; Kim HY; Yang CW; Cho ML Biol Blood Marrow Transplant; 2014 Aug; 20(8):1112-20. PubMed ID: 24813170 [TBL] [Abstract][Full Text] [Related]
11. Caspase-1 inhibition ameliorates murine acute graft versus host disease by modulating the Th1/Th17/Treg balance. Chen W; Su G; Xu Y; Guo W; Bhansali R; Pan B; Kong Q; Cheng H; Cao J; Qi K; Zhu F; Li M; Zhu S; Zeng L; Li Z; Wu Q; Xu K Int Immunopharmacol; 2021 May; 94():107503. PubMed ID: 33647825 [TBL] [Abstract][Full Text] [Related]
12. LYG1 Deficiency Attenuates the Severity of Acute Graft-Versus-Host Disease Liu H; Yu Z; Tang B; Miao S; Qin C; Li Y; Liang Z; Shi Y; Zhang Y; Wang Q; Yan M; Song Z; Ren H; Dong Y Front Immunol; 2021; 12():647894. PubMed ID: 34262560 [TBL] [Abstract][Full Text] [Related]
13. PD-1 and PD-L1 expression on T-cell subsets in women with unexplained recurrent pregnancy losses. Wang WJ; Salazar Garcia MD; Deutsch G; Sung N; Yang X; He Q; Jubiz G; Bilal M; Dambaeva S; Gilman-Sachs A; Beaman K; Kwak-Kim J Am J Reprod Immunol; 2020 May; 83(5):e13230. PubMed ID: 32086851 [TBL] [Abstract][Full Text] [Related]
14. Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice. Wu Y; Bastian D; Schutt S; Nguyen H; Fu J; Heinrichs J; Xia C; Yu XZ Biol Blood Marrow Transplant; 2015 Jul; 21(7):1195-204. PubMed ID: 25846718 [TBL] [Abstract][Full Text] [Related]
15. ADAR1 improved Treg cell function through the miR-21b/Foxp3 axis and inhibits the progression of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Zhao Y; Zheng X; Li M; Zhao J; Wang X; Zhu H Int Immunopharmacol; 2023 Feb; 115():109620. PubMed ID: 36577155 [TBL] [Abstract][Full Text] [Related]
16. MiR-21 Participates in the PD-1/PD-L1 Pathway-Mediated Imbalance of Th17/Treg Cells in Patients After Gastric Cancer Resection. Zheng X; Dong L; Wang K; Zou H; Zhao S; Wang Y; Wang G Ann Surg Oncol; 2019 Mar; 26(3):884-893. PubMed ID: 30565043 [TBL] [Abstract][Full Text] [Related]
17. The role of programmed cell death ligand-1 (PD-L1/CD274) in the development of graft versus host disease. Al-Chaqmaqchi H; Sadeghi B; Abedi-Valugerdi M; Al-Hashmi S; Fares M; Kuiper R; Lundahl J; Hassan M; Moshfegh A PLoS One; 2013; 8(4):e60367. PubMed ID: 23593203 [TBL] [Abstract][Full Text] [Related]
18. IL-17C Mitigates Murine Acute Graft-vs.-Host Disease by Promoting Intestinal Barrier Functions and Treg Differentiation. Gong H; Ma S; Liu S; Liu Y; Jin Z; Zhu Y; Song Y; Lei L; Hu B; Mei Y; Liu H; Liu Y; Wu Y; Dong C; Xu Y; Wu D; Liu H Front Immunol; 2018; 9():2724. PubMed ID: 30534126 [TBL] [Abstract][Full Text] [Related]
19. Efficient treatment of murine acute GvHD by in vitro expanded donor regulatory T cells. Riegel C; Boeld TJ; Doser K; Huber E; Hoffmann P; Edinger M Leukemia; 2020 Mar; 34(3):895-908. PubMed ID: 31719679 [TBL] [Abstract][Full Text] [Related]
20. Blockade of PD-1/PD-L1 increases effector T cells and aggravates murine chronic graft-versus-host disease. Liang Y; Shen J; Lan Q; Zhang K; Xu Y; Duah M; Xu K; Pan B Int Immunopharmacol; 2022 Sep; 110():109051. PubMed ID: 35850051 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]